BTG exceeds revenue forecast

Tuesday 22 May 2012

BTG Plc has exceeded a forecast issued as recently as April and reported revenue of £197 million for the year ended 31 March, up by 77% a year earlier. Revenue was boosted by strong sales of the antibody- fragment treatments, CroFab and DigiFab.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom